Literature DB >> 18043604

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.

Emilio Bajetta1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18043604     DOI: 10.1038/ncponc1007

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


× No keyword cloud information.
  5 in total

Review 1.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

2.  Trends in the treatment and survival for local and regional cutaneous melanoma in a US population-based study.

Authors:  Linda C Harlan; Charles F Lynch; Rachel Ballard-Barbash; Christopher Zeruto
Journal:  Melanoma Res       Date:  2011-12       Impact factor: 3.599

3.  Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.

Authors:  Peter Mohr; Felix Kiecker; Virtudes Soriano; Olivier Dereure; Karmele Mujika; Philippe Saiag; Jochen Utikal; Rama Koneru; Caroline Robert; Florencia Cuadros; Matias Chacón; Rodrigo U Villarroel; Yana G Najjar; Lisa Kottschade; Eva M Couselo; Roy Koruth; Annie Guérin; Rebecca Burne; Raluca Ionescu-Ittu; Maurice Perrinjaquet; Jonathan S Zager
Journal:  Melanoma Manag       Date:  2019-10-04

Review 4.  Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy.

Authors:  Gary Ng; Wen Xu; Victoria Atkinson
Journal:  Curr Oncol Rep       Date:  2022-05-31       Impact factor: 5.945

5.  Role of tumor-associated neutrophils in regulation of tumor growth in lung cancer development: A mathematical model.

Authors:  Yangjin Kim; Donggu Lee; Junho Lee; Seongwon Lee; Sean Lawler
Journal:  PLoS One       Date:  2019-01-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.